DE60325354D1 - Topisch anwendbare pharmazeutische zubereitung - Google Patents

Topisch anwendbare pharmazeutische zubereitung

Info

Publication number: DE60325354D1
Authority: DE; Germany
Prior art keywords: pharmaceutical preparation; topic; applicable pharmaceutical; applicable; administering
Prior art date: 2002-05-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60325354T

Other languages

English (en)

Inventor

Christina Bolle

Rudolf Linder

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Takeda GmbH

Original Assignee

Nycomed GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-05-28

Filing date

2003-05-27

Publication date

2009-01-29

2003-05-27 Application filed by Nycomed GmbH filed Critical Nycomed GmbH

2009-01-29 Application granted granted Critical

2009-01-29 Publication of DE60325354D1 publication Critical patent/DE60325354D1/de

2023-05-28 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F41—WEAPONS
- F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
- F41B5/00—Bows; Crossbows
- F41B5/12—Crossbows
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F41—WEAPONS
- F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
- F41B5/00—Bows; Crossbows
- F41B5/12—Crossbows
- F41B5/123—Compound crossbows
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F41—WEAPONS
- F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
- F41B5/00—Bows; Crossbows
- F41B5/14—Details of bows; Accessories for arc shooting
- F41B5/1442—Accessories for arc or bow shooting
- F41B5/1469—Bow-string drawing or releasing devices

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Ophthalmology & Optometry (AREA)
Immunology (AREA)
Pulmonology (AREA)
General Engineering & Computer Science (AREA)
Otolaryngology (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Dispersion Chemistry (AREA)
Communicable Diseases (AREA)
Cardiology (AREA)
Neurology (AREA)
Vascular Medicine (AREA)
Toxicology (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

DE60325354T 2002-05-28 2003-05-27 Topisch anwendbare pharmazeutische zubereitung Expired - Lifetime DE60325354D1 (de)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
DE10223828		2002-05-28
EP02011830		2002-05-28
DE10311613		2003-03-14
PCT/EP2003/005524 WO2003099334A1 (en)	2002-05-28	2003-05-27	Topically applicable pharmaceutical preparation

Publications (1)

Publication Number	Publication Date
DE60325354D1 true DE60325354D1 (de)	2009-01-29

Family

ID=29587313

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DE60325354T Expired - Lifetime DE60325354D1 (de)	2002-05-28	2003-05-27	Topisch anwendbare pharmazeutische zubereitung
DE60334692T Expired - Lifetime DE60334692D1 (de)	2002-05-28	2003-05-27	Ophthalmologische zubereitung enthaltend roflumilast in der behandlung von krankheiten der augen

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DE60334692T Expired - Lifetime DE60334692D1 (de)	2002-05-28	2003-05-27	Ophthalmologische zubereitung enthaltend roflumilast in der behandlung von krankheiten der augen

Country Status (32)

Country	Link
US (7)	US20060084685A1 (de)
EP (3)	EP1511481B1 (de)
JP (3)	JP2005529928A (de)
KR (2)	KR20050014844A (de)
CN (3)	CN1655823B (de)
AT (2)	ATE417628T1 (de)
AU (2)	AU2003232828B2 (de)
BR (2)	BR0311337A (de)
CA (2)	CA2486910C (de)
CY (2)	CY1110312T1 (de)
DE (2)	DE60325354D1 (de)
DK (3)	DK1511516T3 (de)
EA (2)	EA020569B1 (de)
ES (3)	ES2354971T3 (de)
HR (1)	HRP20041211B1 (de)
HU (1)	HUE039709T2 (de)
IL (3)	IL164935A (de)
IS (1)	IS2639B (de)
LT (1)	LT2020243T (de)
MA (1)	MA27813A1 (de)
ME (1)	ME00565A (de)
MX (2)	MXPA04011528A (de)
NO (2)	NO334882B1 (de)
NZ (3)	NZ536920A (de)
PL (3)	PL397021A1 (de)
PT (3)	PT1511481E (de)
RS (1)	RS51104B (de)
SI (2)	SI1511516T1 (de)
TR (1)	TR201815573T4 (de)
UA (2)	UA88523C2 (de)
WO (2)	WO2003099334A1 (de)
ZA (2)	ZA200408649B (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6872382B1 (en)	2001-05-21	2005-03-29	Alcon, Inc.	Use of selective PDE IV inhibitors to treat dry eye disorders
MY140561A (en)	2002-02-20	2009-12-31	Nycomed Gmbh	Dosage form containing pde 4 inhibitor as active ingredient
MXPA04011528A (es) *	2002-05-28	2005-02-14	Altana Pharma Ag	Preparacion farmaceutica que se puede aplicar por via topica.
KR20050057175A (ko)	2002-09-20	2005-06-16	알콘, 인코퍼레이티드	안구건조증 치료용 사이토카인 합성 저해제의 용도
FR2851247B1 (fr)	2003-02-19	2007-06-29	Exonhit Therapeutics Sa	Methodes et compositions pour le traitement de pathologies degeneratives oculaires
DK1606261T3 (da)	2003-03-10	2010-01-18	Nycomed Gmbh	Hidtil ukendt fremgangsmåde til fremstilling af roflumilast
CA2552524A1 (en) *	2004-01-10	2005-07-28	Biolipid, Inc.	Lipid compositions and methods of use
DE102004046235A1 (de) *	2004-09-22	2006-03-30	Altana Pharma Ag	Arzneimittelzubereitung
DE102004046236A1 (de) *	2004-09-22	2006-03-30	Altana Pharma Ag	Arzneimittelzubereitung
NZ560269A (en) *	2005-03-08	2010-12-24	Nycomed Gmbh	Roflumilast for the treatment of diabetes mellitus
EP2258350B1 (de) *	2005-03-16	2014-12-24	Takeda GmbH	Geschmacksmaskierte Dosierform mit Roflumilast
KR20080029974A (ko) *	2005-06-09	2008-04-03	산텐 세이야꾸 가부시키가이샤	로플루밀라스트 점안액
EP1992622B1 (de)	2006-02-21	2011-07-27	Eisai R&D Management Co., Ltd.	4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminochinazolinderivat
WO2008099887A1 (ja)	2007-02-16	2008-08-21	Eisai R & D Management Co., Ltd.	メチルｎ－［３－（６，７－ジメトキシ－２－メチルアミノキナゾリン－４－イル）フェニル］テレフタラミックアシッドの結晶、非晶質体または塩
AU2008290000B2 (en)	2007-08-17	2012-05-10	Eisai R & D Management Co., Ltd.	Method for producing quinazoline derivative
WO2009025239A1 (ja)	2007-08-17	2009-02-26	Eisai R & D Management Co., Ltd.	新規外用剤
MX2012004777A (es)	2009-10-30	2012-06-01	Nestec Sa	Metodos para mantener la salud de los ojos y mejorar enfermedades oftalmicas en caninos.
ES2408132B1 (es) *	2010-09-08	2014-04-04	Universidad Miguel Hernández De Elche	Composición farmacéutica para el tratamiento de la epífora.
ES2377785B2 (es)	2010-09-08	2012-09-26	Universidad Miguel Hernández De Elche	Composición farmacéutica para el tratamiento del ojo seco.
EP3320902B1 (de)	2011-03-07	2021-02-17	Amgen (Europe) GmbH	Verfahren zur behandlung von erkrankungen mit isoindolinverbindungen
CN102793684B (zh) *	2011-05-26	2016-02-17	杭州赛利药物研究所有限公司	罗氟司特液体制剂及其制备方法
US20140296301A1 (en) *	2011-06-28	2014-10-02	Bayer Pharma Aktiengesellschaft	Topical ophthalmological pharmaceutical composition containing regoragenib
WO2013155123A1 (en) *	2012-04-10	2013-10-17	Georgia State University Research Foundation, Inc.	Compositions and methods for treating otitis media and other conditions with inhibitors of cyld
CN103570610B (zh) *	2012-07-18	2017-08-11	重庆华邦制药有限公司	一种罗氟司特微粒的制备方法
WO2014012954A1 (en)	2012-07-18	2014-01-23	Takeda Gmbh	Treatment of partly controlled or uncontrolled severe asthma
JP6434416B2 (ja)	2012-11-08	2018-12-05	ライゼン・ファーマシューティカルズ・エスアー	ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物
TW201540301A (zh)	2013-08-16	2015-11-01	Takeda Gmbh	以ｐｄｅ４抑制劑治療認知損傷
CN105434328A (zh) *	2014-09-01	2016-03-30	天津药物研究院有限公司	一种含罗氟司特固体分散体的固体制剂及其制备方法
KR101878621B1 (ko) *	2014-10-24	2018-07-13	히사미쓰 세이야꾸 가부시키가이샤	프로드러그
CN104997959A (zh) *	2015-08-21	2015-10-28	蔡宇平	一种用于治疗睑板腺囊肿的中药
CN106148528B (zh) *	2016-07-11	2019-10-01	赵晨	一种遗传性Usher综合征的致病突变及其检测试剂
US11129818B2 (en)	2017-06-07	2021-09-28	Arcutis Biotherapeutics, Inc.	Topical roflumilast formulation having improved delivery and plasma half life
US9895359B1 (en)	2017-06-07	2018-02-20	Arcutis, Inc.	Inhibition of crystal growth of roflumilast
US12011437B1 (en)	2017-06-07	2024-06-18	Arcutis Biotherapeutics, Inc.	Roflumilast formulations with an improved pharmacokinetic profile
US20200155524A1 (en) *	2018-11-16	2020-05-21	Arcutis, Inc.	Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US12042487B2 (en)	2018-11-16	2024-07-23	Arcutis Biotherapeutics, Inc.	Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US20210161870A1 (en)	2017-06-07	2021-06-03	Arcutis Biotherapeutics, Inc.	Roflumilast formulations with an improved pharmacokinetic profile
US11534493B2 (en) *	2017-09-22	2022-12-27	Arcutis Biotherapeutics, Inc.	Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
CN108283620A (zh) *	2018-03-13	2018-07-17	兆科药业（广州）有限公司	一种磷酸二酯酶-4抑制剂的局部药物组合物及其制备方法
WO2019236374A2 (en)	2018-06-04	2019-12-12	Arcutis, Inc.	Method and formulation for improving roflumilast skin penetration lag time
KR102117525B1 (ko) *	2018-07-09	2020-06-01	건양대학교 산학협력단	Pde4b 저해제를 유효성분으로 함유하는 만성 부비동염에서의 비용종 발생의 예방 및 치료용 약학 조성물
EP4096630A1 (de) *	2020-01-31	2022-12-07	Arcutis Biotherapeutics, Inc.	Topische roflumilast-formulierung, die eine verbesserte abgabe und plasmahalbwertszeit aufweist
CA3153934C (en) *	2020-05-07	2023-01-31	David W. Osborne	Treatment of skin conditions using high krafft temperature anionic surfactants
CN116963717A (zh)	2020-12-04	2023-10-27	阿尔库缇斯生物疗法股份有限公司	具有抗真菌性能的局部用罗氟司特制剂
WO2022169615A1 (en)	2021-02-05	2022-08-11	Arcutis Biotherapeutics, Inc.	Roflumilast formulations with an improved pharmacokinetic profile
CA3206106A1 (en) *	2021-02-10	2022-08-18	Bhaskar Chaudhuri	Methods for ophthalmic delivery of roflumilast
CN116867480A (zh) *	2021-02-10	2023-10-10	洛利克斯治疗有限公司	眼部递送罗氟司特的方法
EP4351612A4 (de) *	2021-06-01	2025-05-07	Eyedea Bio, Llc	System zur verabreichung von arzneimitteln mit verlängerter freisetzung für augenarzneimittel und verfahren zur verwendung
AU2022353032A1 (en) *	2021-09-22	2024-03-28	Iolyx Therapeutics, Inc.	Methods of treating ocular inflammatory diseases
EP4447935A1 (de)	2021-12-17	2024-10-23	Aerie Pharmaceuticals, Inc.	Ophthalmische pharmazeutische zusammensetzungen und verwendungen davon
EP4456870A1 (de)	2021-12-28	2024-11-06	Arcutis Biotherapeutics, Inc.	Topische roflumilast-aerosolschäume
JP2025530005A (ja)	2022-09-15	2025-09-09	アーキュティス・バイオセラピューティクス・インコーポレーテッド	ロフルミラスト及び大量のロフルミラストを溶解可能な溶媒の医薬組成物
US20250082618A1 (en)	2023-09-07	2025-03-13	Arcutis Biotherapeutics, Inc.	Dosing regimens using topical roflumilast compositions
US20250090508A1 (en)	2023-09-15	2025-03-20	Arcutis Biotherapeutics, Inc.	Methods of reducing itch using topical roflumilast compositions
US20250120957A1 (en)	2023-10-12	2025-04-17	Alto Neuroscience, Inc.	Treatment of neuropsychiatric disorders with tilivapram
CN117462487A (zh) *	2023-11-29	2024-01-30	沈阳药科大学	一种罗氟司特油凝胶及其制备方法
WO2025221488A1 (en)	2024-04-16	2025-10-23	Alto Neuroscience, Inc.	Transdermal administration of pde4 inhibitors for reduction in adverse events
WO2025265054A2 (en)	2024-06-21	2025-12-26	Arcutis Biotherapeutics, Inc.	Methods of treatment using topical roflumilast compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4753945A (en) *	1986-02-19	1988-06-28	Eye Research Institute Of Retina Foundation	Stimulation of tear secretion with phosphodiesterase inhibitors
US5011843A (en) *	1988-05-31	1991-04-30	Iolab Corporation	Treatment of glaucoma using phosphodiesterase inhibitors
US5891904A (en) *	1992-09-14	1999-04-06	Wolf-Georg Forssmann	Use of inhibitors of phosphodiesterase IV
PL178314B1 (pl) *	1993-07-02	2000-04-28	Byk Gulden Lomberg Chem Fab	Benzamidy podstawione grupą fluoroalkoksylową, hamujące fosfodiesterazę cyklicznych nukleotydów, sposób ich otrzymywania i lek zawierający podstawione benzamidy
EP0719561A4 (de) *	1993-08-10	1997-07-30	Fujisawa Pharmaceutical Co	Perkutan absorbierend Zubereitung
ZA954599B (en) *	1994-06-07	1996-01-26	Allergan Inc	Stable gel formulation for topical treatment of skin conditions
WO2000018768A1 (en) *	1998-09-29	2000-04-06	Fujisawa Pharmaceutical Co., Ltd.	Novel salts of pyridopyrazine compound and crystals thereof
US6395746B1 (en) *	1998-09-30	2002-05-28	Alcon Manufacturing, Ltd.	Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US20020006418A1 (en) *	1998-10-13	2002-01-17	John Kung	Composition to enhance permeation of topical skin agents
JP2002538207A (ja)	1999-03-10	2002-11-12	ビイクグルデンロンベルクヒエーミツシエフアブリークゲゼルシヤフトミツトベシユレンクテルハフツング	多発性硬化症治療のための３−シクロプロピルメトキシ−４−ジフルオロメトキシ−ｎ−（３，５−ジクロロピリド−４−イル）ベンズアミド
US6174878B1 (en) *	1999-08-31	2001-01-16	Alcon Laboratories, Inc.	Topical use of kappa opioid agonists to treat otic pain
NZ518002A (en) *	1999-10-29	2004-01-30	Smithkline Beecham Corp	Method for administering a phosphodiesterase 4 inhibitor
ATE269860T1 (de) *	2000-01-31	2004-07-15	Pfizer Prod Inc	Pyrimidinylcarboxamiden als inhibitoren der pde4 isoenzyme
WO2001060358A1 (en) *	2000-02-16	2001-08-23	University Of Nebraska Medical Center	Method and compositions for treating fibrotic diseases
AU6196201A (en) *	2000-05-25	2001-12-03	Merck Frosst Canada Inc	Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
WO2002038155A1 (en) *	2000-11-07	2002-05-16	Merck & Co., Inc.	Method of treatment with a combination of a pde4 inhibitor and a leukotriene antagonist
UA77656C2 (en) *	2001-04-07	2007-01-15	Glaxo Group Ltd	S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US6872382B1 (en) *	2001-05-21	2005-03-29	Alcon, Inc.	Use of selective PDE IV inhibitors to treat dry eye disorders
US20030092706A1 (en) *	2001-11-09	2003-05-15	Johannes Barsig	Combination
MXPA04011528A (es) *	2002-05-28	2005-02-14	Altana Pharma Ag	Preparacion farmaceutica que se puede aplicar por via topica.

2003
- 2003-05-27 MX MXPA04011528A patent/MXPA04011528A/es active IP Right Grant
- 2003-05-27 US US10/515,896 patent/US20060084685A1/en not_active Abandoned
- 2003-05-27 CN CN038124068A patent/CN1655823B/zh not_active Expired - Fee Related
- 2003-05-27 PT PT03730122T patent/PT1511481E/pt unknown
- 2003-05-27 WO PCT/EP2003/005524 patent/WO2003099334A1/en not_active Ceased
- 2003-05-27 HU HUE08166780A patent/HUE039709T2/hu unknown
- 2003-05-27 CA CA2486910A patent/CA2486910C/en not_active Expired - Fee Related
- 2003-05-27 ES ES03730122T patent/ES2354971T3/es not_active Expired - Lifetime
- 2003-05-27 BR BR0311337-0A patent/BR0311337A/pt not_active Application Discontinuation
- 2003-05-27 LT LTEP08166780.0T patent/LT2020243T/lt unknown
- 2003-05-27 AU AU2003232828A patent/AU2003232828B2/en not_active Ceased
- 2003-05-27 JP JP2004506802A patent/JP2005529928A/ja active Pending
- 2003-05-27 PT PT03755048T patent/PT1511516E/pt unknown
- 2003-05-27 SI SI200331532T patent/SI1511516T1/sl unknown
- 2003-05-27 HR HRP20041211AA patent/HRP20041211B1/hr not_active IP Right Cessation
- 2003-05-27 EA EA200702588A patent/EA020569B1/ru not_active IP Right Cessation
- 2003-05-27 JP JP2004506857A patent/JP5652983B2/ja not_active Expired - Lifetime
- 2003-05-27 DK DK03755048T patent/DK1511516T3/da active
- 2003-05-27 TR TR2018/15573T patent/TR201815573T4/tr unknown
- 2003-05-27 DE DE60325354T patent/DE60325354D1/de not_active Expired - Lifetime
- 2003-05-27 NZ NZ536920A patent/NZ536920A/en not_active IP Right Cessation
- 2003-05-27 AU AU2003240719A patent/AU2003240719B2/en not_active Ceased
- 2003-05-27 PL PL397021A patent/PL397021A1/pl unknown
- 2003-05-27 EP EP03730122A patent/EP1511481B1/de not_active Expired - Lifetime
- 2003-05-27 ES ES08166780.0T patent/ES2693094T3/es not_active Expired - Lifetime
- 2003-05-27 KR KR10-2004-7019272A patent/KR20050014844A/ko not_active Ceased
- 2003-05-27 UA UAA200712909A patent/UA88523C2/ru unknown
- 2003-05-27 MX MXPA04011612A patent/MXPA04011612A/es active IP Right Grant
- 2003-05-27 EA EA200401517A patent/EA010416B1/ru not_active IP Right Cessation
- 2003-05-27 KR KR1020117025130A patent/KR101307093B1/ko not_active Expired - Fee Related
- 2003-05-27 ES ES03755048T patent/ES2319517T3/es not_active Expired - Lifetime
- 2003-05-27 UA UA20041210683A patent/UA81910C2/uk unknown
- 2003-05-27 WO PCT/EP2003/005536 patent/WO2003099278A1/en not_active Ceased
- 2003-05-27 CN CN2009100043805A patent/CN101491520B/zh not_active Expired - Fee Related
- 2003-05-27 CN CNB038120941A patent/CN100490804C/zh not_active Expired - Fee Related
- 2003-05-27 EP EP08166780.0A patent/EP2020243B1/de not_active Expired - Lifetime
- 2003-05-27 CA CA2486917A patent/CA2486917C/en not_active Expired - Fee Related
- 2003-05-27 PL PL372082A patent/PL211870B1/pl unknown
- 2003-05-27 RS YUP-1014/04A patent/RS51104B/sr unknown
- 2003-05-27 NZ NZ537308A patent/NZ537308A/en not_active IP Right Cessation
- 2003-05-27 BR BR0311339-6A patent/BR0311339A/pt not_active Application Discontinuation
- 2003-05-27 PT PT08166780T patent/PT2020243T/pt unknown
- 2003-05-27 NZ NZ553731A patent/NZ553731A/en not_active IP Right Cessation
- 2003-05-27 DK DK08166780.0T patent/DK2020243T3/en active
- 2003-05-27 AT AT03755048T patent/ATE417628T1/de active
- 2003-05-27 ME MEP-854/08A patent/ME00565A/xx unknown
- 2003-05-27 SI SI200332580T patent/SI2020243T1/sl unknown
- 2003-05-27 US US10/515,698 patent/US20060084684A1/en not_active Abandoned
- 2003-05-27 PL PL372095A patent/PL212134B1/pl unknown
- 2003-05-27 DK DK03730122.3T patent/DK1511481T3/da active
- 2003-05-27 DE DE60334692T patent/DE60334692D1/de not_active Expired - Lifetime
- 2003-05-27 EP EP03755048A patent/EP1511516B1/de not_active Expired - Lifetime
- 2003-05-27 AT AT03730122T patent/ATE485821T1/de active
2004
- 2004-10-21 MA MA27912A patent/MA27813A1/fr unknown
- 2004-10-26 ZA ZA200408649A patent/ZA200408649B/xx unknown
- 2004-10-31 IL IL164935A patent/IL164935A/en not_active IP Right Cessation
- 2004-11-07 IL IL165065A patent/IL165065A/en active IP Right Grant
- 2004-11-26 ZA ZA200409584A patent/ZA200409584B/xx unknown
- 2004-12-16 NO NO20045506A patent/NO334882B1/no not_active IP Right Cessation
- 2004-12-23 IS IS7612A patent/IS2639B/is unknown
- 2004-12-27 NO NO20045656A patent/NO334916B1/no not_active IP Right Cessation
2008
- 2008-04-29 US US12/149,250 patent/US20080280958A1/en not_active Abandoned
2009
- 2009-03-10 CY CY20091100273T patent/CY1110312T1/el unknown
2010
- 2010-11-30 IL IL209657A patent/IL209657A0/en unknown
2011
- 2011-08-26 US US13/219,056 patent/US20110313005A1/en not_active Abandoned
2012
- 2012-07-09 JP JP2012154020A patent/JP5683538B2/ja not_active Expired - Lifetime
2013
- 2013-11-08 US US14/075,035 patent/US20140303215A1/en not_active Abandoned
2018
- 2018-10-03 US US16/150,759 patent/US20190029956A1/en not_active Abandoned
- 2018-10-24 CY CY181101093T patent/CY1121133T1/el unknown
2020
- 2020-06-03 US US16/891,823 patent/US20210116207A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN1655823A (zh)	2005-08-17
PL397021A1 (pl)	2012-03-26
AU2003232828B2 (en)	2010-06-24
CN101491520A (zh)	2009-07-29
KR20110122230A (ko)	2011-11-09
ME00565A (en)	2011-12-20
ES2354971T3 (es)	2011-03-21
DE60334692D1 (de)	2010-12-09
CN1655823B (zh)	2010-05-26
BR0311337A (pt)	2005-03-15
SI1511516T1 (sl)	2009-06-30
IS2639B (is)	2010-06-15
IL165065A (en)	2010-11-30
IL209657A0 (en)	2011-02-28
EA010416B1 (ru)	2008-08-29
EP1511516B1 (de)	2008-12-17
HRP20041211A2 (hr)	2006-04-30
RS101404A (sr)	2007-02-05
IS7612A (is)	2004-12-23
DK1511516T3 (da)	2009-04-06
PL372095A1 (en)	2005-07-11
MA27813A1 (fr)	2006-04-03
CA2486917C (en)	2011-11-22
NO20045656L (no)	2004-12-27
ATE417628T1 (de)	2009-01-15
KR101307093B1 (ko)	2013-09-11
EA200401517A1 (ru)	2005-06-30
EP1511481B1 (de)	2010-10-27
ES2693094T3 (es)	2018-12-07
JP5683538B2 (ja)	2015-03-11
BR0311339A (pt)	2005-03-22
JP2012229245A (ja)	2012-11-22
EA020569B1 (ru)	2014-12-30
NZ537308A (en)	2009-09-25
NZ553731A (en)	2007-07-27
IL165065A0 (en)	2005-12-18
PL372082A1 (en)	2005-07-11
NO334916B1 (no)	2014-07-14
PT1511481E (pt)	2011-01-14
AU2003240719B2 (en)	2009-12-10
EA200702588A1 (ru)	2008-08-29
ES2319517T3 (es)	2009-05-08
DK1511481T3 (da)	2011-01-24
JP5652983B2 (ja)	2015-01-14
EP2020243A1 (de)	2009-02-04
JP2005529930A (ja)	2005-10-06
HK1079437A1 (en)	2006-04-07
JP2005529928A (ja)	2005-10-06
IL164935A0 (en)	2005-12-18
HK1079445A1 (zh)	2006-04-07
SI2020243T1 (sl)	2018-11-30
UA81910C2 (uk)	2008-02-25
RS51104B (sr)	2010-10-31
KR20050014844A (ko)	2005-02-07
ZA200408649B (en)	2007-12-27
ZA200409584B (en)	2006-05-31
HRP20041211B1 (hr)	2013-06-30
MXPA04011528A (es)	2005-02-14
CN1655782A (zh)	2005-08-17
US20110313005A1 (en)	2011-12-22
US20080280958A1 (en)	2008-11-13
PL212134B1 (pl)	2012-08-31
NO20045506L (no)	2004-12-16
NZ536920A (en)	2007-04-27
LT2020243T (lt)	2018-11-12
CA2486910A1 (en)	2003-12-04
AU2003232828A1 (en)	2003-12-12
PL211870B1 (pl)	2012-07-31
CN100490804C (zh)	2009-05-27
PT1511516E (pt)	2009-02-20
EP1511481A1 (de)	2005-03-09
MXPA04011612A (es)	2005-03-07
DK2020243T3 (en)	2018-11-19
HUE039709T2 (hu)	2019-01-28
EP2020243B1 (de)	2018-08-15
WO2003099278A1 (en)	2003-12-04
US20210116207A1 (en)	2021-04-22
US20140303215A1 (en)	2014-10-09
ATE485821T1 (de)	2010-11-15
WO2003099334A1 (en)	2003-12-04
UA88523C2 (ru)	2009-10-26
US20060084685A1 (en)	2006-04-20
CY1121133T1 (el)	2019-12-11
CA2486917A1 (en)	2003-12-04
TR201815573T4 (tr)	2018-11-21
US20190029956A1 (en)	2019-01-31
CA2486910C (en)	2011-11-29
AU2003240719A1 (en)	2003-12-12
PT2020243T (pt)	2018-11-09
CY1110312T1 (el)	2015-01-14
NO334882B1 (no)	2014-06-30
US20060084684A1 (en)	2006-04-20
IL164935A (en)	2010-12-30
CN101491520B (zh)	2011-03-16
EP1511516A1 (de)	2005-03-09

Publication	Publication Date	Title
DE60325354D1 (de)	2009-01-29	Topisch anwendbare pharmazeutische zubereitung
UA84266C2 (uk)	2008-10-10	Дозована лікарська форма у вигляді таблетки або пелети для перорального введення, яка містить інгібітор pde 4 та полівінілпіролідон, способи її одержання та застосування
DK1341542T3 (da)	2007-09-03	Indanylderivater til behandling af luftvejssygdomme
AU2002211863A1 (en)	2002-04-15	Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
ATE516017T1 (de)	2011-07-15	Feste pharmazeutische dosierform enthaltende ritonavir
DE60209145D1 (de)	2006-04-20	Pharmazeutische formulierungen mit platinderivaten
ATE337016T1 (de)	2006-09-15	Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen
PA8589401A1 (es)	2004-07-20	Derivados de indolilo
ECSP045447A (es)	2005-01-28	Preparación farmacéutica que se puede aplicar por vía tópica
ITMI931104A1 (it)	1994-11-28	Preparazione di una forma farmaceutica atta a combattere l'iperinsulinismo

Legal Events

Date	Code	Title	Description
2010-01-07	8364	No opposition during term of opposition